SBP Group (01177) has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has entered into an exclusive licensing and supply agreement with Cipla Limited for the company's self-developed HER2 bispecific antibody-drug conjugate, rolditamig deuderuxtecan (development code: TQB2102). This marks the second regional licensing collaboration for TQB2102, with the two agreements collectively generating approximately $30 million in upfront and milestone payments so far, underscoring the asset's commercial potential and the group's strategic regional partnership approach.

Under the terms of the agreement, SBP Group will grant Cipla an exclusive license to develop and commercialize TQB2102 in India, South Africa, and five other emerging markets. Cipla will oversee local clinical development, regulatory filings, and commercialization within the licensed territories, while Chia Tai Tianqing will remain responsible for the manufacturing and supply of TQB2102. The group is entitled to upfront payments, potential development, regulatory, and sales milestone payments of up to $123 million, in addition to double-digit royalties based on annual net sales of TQB2102.

This collaboration advances the group's internationalization strategy, leveraging the partners' strong local capabilities and market access advantages to accelerate the delivery of late-stage innovative therapies to patients globally. Cipla's years of experience in India, South Africa, and other emerging markets, supported by mature regulatory, medical, and commercial systems, provides a solid foundation for expediting the development and commercialization of TQB2102 in these regions. Subject to regulatory approvals, this partnership is expected to enhance the global accessibility of this potential best-in-class HER2 ADC, while bolstering the group's international expansion and long-term value creation.

Founded in 1935, Cipla is a global pharmaceutical company focused on flexible and sustainable growth, with a strong emphasis on complex generics and a deepening product portfolio across its home markets of India, South Africa, North America, and other key mature and emerging markets. The company has established expertise in therapeutic areas such as respiratory, antiretroviral, urology, cardiovascular, anti-infective, and central nervous system treatments, earning a strong industry reputation. Cipla operates 48 manufacturing sites worldwide, producing over 50 dosage forms and more than 1,500 products, with a presence in over 70 markets. It is the third-largest pharmaceutical company in India, the second-largest in the South African prescription market, and ranks second in the U.S. generic inhalation and metered-dose inhaler market by prescription volume.

For nine decades, Cipla has remained committed to transforming patient lives. In 2001, it became the first company in Africa to introduce a triple antiretroviral therapy for HIV/AIDS, reducing daily treatment costs to under one dollar, a pioneering move widely credited with dramatically improving the inclusivity, accessibility, and affordability of global AIDS treatment. As a responsible corporate citizen, Cipla upholds its mission of "Caring for Life," integrating humanitarian values into its healthcare activities and actively engaging with local communities across its operational regions, earning widespread trust from global health organizations, industry peers, and stakeholders.

TQB2102 is SBP Group's self-developed next-generation HER2 bispecific ADC, targeting both the ECD II and ECD IV domains of HER2 simultaneously, using a cleavable linker and topoisomerase I inhibitor payload. This differentiated design overcomes the limitations of traditional HER2 monoclonal antibodies or single-target ADCs, with the bispecific binding mode enhancing receptor cross-linking and internalization efficiency, providing clear differentiation in treating HER2-low expressing patients. At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, the group presented Phase Ib clinical results for TQB2102 in HER2-low advanced breast cancer, demonstrating favorable efficacy and safety. In heavily pretreated HER2-low patients, the overall response rate was 53.4%, with notable activity even in patients who progressed after prior ADC therapy, where 44.4% achieved a response. Safety data showed only one case of grade 2 interstitial lung disease (0.55% incidence), significantly lower than other HER2 ADCs.

TQB2102 has received three breakthrough therapy designations from China's Center for Drug Evaluation (CDE). Multiple Phase III studies are underway across HER2-low breast cancer, HER2-positive breast cancer, colorectal cancer, and biliary tract cancer. The group will present Phase III data for TQB2102 in HER2-low breast cancer at the 2026 European Society for Medical Oncology (ESMO) congress as a late-breaking abstract.